Global Venous Thromboembolism Treatment Market
Venous thromboembolism is a disease caused by the clotting of blood in the blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years. People with overweight, persons with thicker blood and the persons suffering from autoimmune disorders such as (lupus, rheumatoid arthritis etc.) or cancer are at higher risk of venous thromboembolism. Venous thromboembolism can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, oedema, fever, tachycardia, and dyspnoea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral veins.
The venous thromboembolism treatment market is growing at a significant CAGR due to increase in geriatric population. A rise in the government expenditure, increase in the incidence of venous thromboembolism are fuelling the Venous Thromboembolism (VTE) Treatment Market. Furthermore, increase in surgical procedures such as hip and knee replacements that are risk factors for venous thromboembolism conditions, growing patient awareness venous thromboembolism conditions expected to boost the venous thromboembolism treatment market growth over the forecast period. However, a high cost of deep vein thrombosis treatment, high unmet needs of currently available treatment procedures, and adverse effects associated with drugs hinder the growth of venous thromboembolism treatment market. Similarly, stringent regulatory approvals, the presence of alternatives treatments such as thrombectomy and percutaneous techniques are hindering the growth of venous thromboembolism drugs market over the forecast period.
The global Venous Thromboembolism (VTE) Treatment Market is segmented on the basis of drug type, disease type, and distribution channel
Based on drug type, venous thromboembolism drugs market is segmented into the following:
- Factor Xa inhibitors
- Thrombolytic therapy
- Plasminogen activators
Based on disease type, the venous thromboembolism drugs market is segmented into the following:
- Deep vein thrombosis
- Pulmonary embolism
Based on distribution channel, the venous thromboembolism drugs market is segmented into the following:
- Hospital pharmacies
- Online Pharmacies
- Retail pharmacies
The growth of global venous thromboembolism treatment market is due to rise in prevalence of venous thromboembolism (According to the International Society of Thrombosis and Haemostasis, Inc.(ISTH), approximately 10 Mn cases of venous thromboembolism occur annually). The most commonly adopted strategies by industry players include new product launches with technological innovations, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism treatment market share. For instance, in March 2017, The Apex trial reported that extended use of betrixaban beyond the parenteral prophylaxis with enoxaparin reduces the venous thromboembolism incidence among the patients. Similarly, in May 2011, Eliquis (apixaban) Approved In Europe for preventing venous thromboembolism after elective knee or hip replacement. Also, in January 2015, Bayer forms the collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source.
Geographically, global venous thromboembolism treatment market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. North America anticipated to hold the largest share in the venous thromboembolism treatment market owing to increase in the incidence (According to U.S. International Society on Thrombosis and Haemostasis, Inc. (ISTH) there are around 100,000 to 300,000 venous thromboembolism related deaths reported annually) and prevalence rate, rise in demand for advanced treatments, an increase in aging population in the North America region. Moreover, a rise in healthcare expenditure, growing awareness regarding the disease and treatments, and increase in prevalence rate in the Europe region drives the Global Venous Thromboembolism Drugs Market over the forecast period. Asia-Pacific is a key region for venous thromboembolism treatment market due to increase in the government expenditure and healthcare infrastructure. However, a high cost of the venous thromboembolism treatment and low awareness regarding venous thromboembolism treatment among key stakeholders are the key factors hindering the venous thromboembolism treatment market growth in Latin America and the Middle East and Africa regions.
Some of the players in global venous thromboembolism treatment market are Sanofi (France), Pfizer Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan) , Bristol Myers Squibb (U.S.), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Merck & Co. (U.S.), Astellas Pharma Inc. (Japan), Sawai Pharmaceuticals Co. Ltd. (U.S.), Abbott Laboratories (U.S.), Wockhardt Ltd (India), Bayer AG (Germany), and Dupont (U.S.) to name a few.
Market players such as Pfizer Japan Inc., Boehringer-Ingelheim and few others are focusing on untapped markets and geographies to capitalize the market opportunities along with attaining significant market shares during the forecast period.
- In June 2017, U.S. FDA granted priority review of Xarelto (Rivaroxaban) NDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism
- In February 2016, Bristol Myers Squibb and Pfizer, Inc. collaborated with Portola Pharmaceuticals Inc. for the development and commercialization of investigational drug Andexanet Alfa in the Japan
- In May 2015, Bayer’s Xarelto approved in China for stroke prevention in patients with non-valvular atrial fibrillation and for the treatment of deep vein thrombosis
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario